Clinical implications of blood eosinophil count in patients with non-asthma–COPD overlap syndrome COPD

International Journal of COPD

Volumn 12, Issue , 2017, Pages 2455-2464

  Song, Jin Hwa ^a   Lee, Chang Hoon ^a   Kim, Jin Woo ^b   Lee, Won Yeon ^c   Jung, Ji Ye ^d   Park, Joo Hun ^e   Jung, Ki Suck ^f   Yoo, Kwang Ha ^g   Park, Yong Bum ^h   Kim, Deog Keom ⁱ  

^a Seoul National University Hospital   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Yonsei University Wonju College of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Ajou University School of Medicine   (South Korea)

^f Hallym University Sacred Heart Hospital   (South Korea)

^g Konkuk University Hospital   (South Korea)

^h Kangdong Sacred Heart Hospital   (South Korea)

ⁱ Seoul National University Boramae Hospital   (South Korea)

Author keywords

Acute exacerbation; Asthma; Chronic obstructive lung disease; Eosinophil; Inhaled corticosteroid

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON ASTHMA CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP SYNDROME; OBSERVATIONAL STUDY; PREDICTION; PROSPECTIVE STUDY; RISK FACTOR; BLOOD; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; DRUG EFFECT; EOSINOPHIL; INHALATIONAL DRUG ADMINISTRATION; LEUKOCYTE COUNT; LUNG; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ODDS RATIO; PATHOPHYSIOLOGY; PREDICTIVE VALUE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SOUTH KOREA; STATISTICAL MODEL; VITAL CAPACITY;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; EOSINOPHILS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LEUKOCYTE COUNT; LOGISTIC MODELS; LUNG; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; REPUBLIC OF KOREA; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VITAL CAPACITY;

EID: 85028340914     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S129321     Document Type: Article

References (33)

1. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinico-econ Outcomes Res. 2013;5:235–245.
2. Bourbeau J, Ford G, Zackon H, Pinsky N, Lee J, Ruberto G. Impact on patients’ health status following early identification of a COPD exacerbation. Eur Respir J. 2007;30(5):907–913.
3. Donaldson G, Seemungal T, Bhowmik A, Wedzicha J. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852.
4. Jinjuvadia C, Jinjuvadia R, Mandapakala C, Durairajan N, Liangpunsakul S, Soubani AO. Trends in outcomes, financial burden, and mortality for acute exacerbation of chronic obstructive pulmonary disease (COPD) in the United States from 2002 to 2010. COPD. 2017; 14(1):72–79.
5. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–671.
6. Thomsen M, Ingebrigtsen TS, Marott JL, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA. 2013;309(22):2353–2361.
7. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest. 2007;131(4):1058–1067.
8. Schleich F, Corhay JL, Louis R. Blood eosinophil count to predict bronchial eosinophilic inflammation in COPD. Eur Respir J. 2016; 45(5):1562–1564.
9. Barnes NC, Sharma R, Lettis S, Calverley PM. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J. 2016;37(5):1374–1382.
10. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6): 435–442.
11. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(1):48–55.
12. Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in COPD: the Copenhagen General Population Study. Am J Respir Crit Care Med. 2016;193(9):965–974.
13. Pavord ID, Lettis S, Locantore N, et al. Blood eosinophils and inhaled cor-ticosteroid/long-acting beta-2 agonist efficacy in COPD. Thorax. 2016; 71(2):118–125.
14. Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390–398.
15. Salturk C, Karakurt Z, Adiguzel N, et al. Does eosinophilic COPD exacerbation have a better patient outcome than non-eosinophilic in the intensive care unit? Int J Chron Obstruct Pulmon Dis. 2015;10: 1837–1846.
16. Soler-Cataluna JJ, Cosio B, Izquierdo JL, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol. 2012;48(9):331–337.
17. Sin DD, Miravitlles M, Mannino DM, et al. What is asthma−COPD overlap syndrome? Towards a consensus definition from a round-table discussion. Eur Respir J. 2016;48(3):664–673.
18. Golpe R, Sanjuan Lopez P, Cano Jimenez E, Castro Anon O, Perez de Llano LA. Distribution of clinical phenotypes in patients with chronic obstructive pulmonary disease caused by biomass and tobacco smoke. Arch Bronconeumol. 2014;50(8):318–324.
19. Cosio BG, Soriano JB, López-Campos JL, et al; CHAIN Study. Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort. Chest. 2016;149(1):45–52.
20. Marsh SE, Travers J, Weatherall M, et al. Proportional classifications of COPD phenotypes. Thorax. 2008;63(9):761–767.
21. Postma DS, Rabe KF. The Asthma-COPD overlap syndrome. N Engl J Med. 2015;373(13):1241–1249.
22. Bafadhel M, Greening NJ, Harvey-Dunstan TC, et al. Blood eosinophils and outcomes in severe hospitalised exacerbations of COPD. Chest. 2016;150(2):320–328.
23. Lee JY, Chon GR, Rhee CK, et al. Characteristics of patients with chronic obstructive pulmonary disease at the first visit to a pulmonary medical center in Korea: The KOrea COpd Subgroup Study Team Cohort. J Korean Med Sci. 2016;31(4):553–560.
24. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) [homepage on the Internet]. 2017. Available from: http://goldcopd.org. Accessed April 5, 2017.
25. Zeiger RS, Schatz M, Li Q, et al. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma. J Allergy Clin Immunol Pract. 2014;2(6):741–750.
26. DiSantostefano RL, Hinds D, Van Le H, Barnes NC. Relationship between blood eosinophils and clinical characteristics in a cross-sectional study of a US population-based COPD cohort. Respir Med. 2016;112:88–96.
27. George L, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis. 2016;7(1):34–51.
28. Miravitlles M, Soler-Cataluna JJ, Calle M, et al. Spanish guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol. 2014;50(suppl 1): 1–16.
29. Lavinskiene S, Malakauskas K, Jeroch J, Hoppenot D, Sakalauskas R. Functional activity of peripheral blood eosinophils in allergen-induced late-phase airway inflammation in asthma patients. J Inflamm (Lond). 2015;12:25.
30. Pavord ID, Lettis S, Anzueto A, Barnes N. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med. 2016;4(9):731–741.
31. Nurwidya F, Damayanti T, Yunus F. The role of innate and adaptive immune cells in the immunopathogenesis of chronic obstructive pulmonary disease. Tuberc Respir Dis (Seoul). 2016;79(1):5–13.
32. Wurst KE, Kelly-Reif K, Bushnell GA, Pascoe S, Barnes N. Understanding asthma-chronic obstructive pulmonary disease overlap syndrome. Respir Med. 2016;110:1–11.
33. van der Heide S, de Monchy JGR, de Vries K, Bruggink TM, Kauffman HF. Seasonal variation in airway hyperresponsiveness and natural exposure to house dust mite allergens in patients with asthma. J Allergy ClinImmunol. 1994;93(2):470–475.